Android app on Google Play

Leerink Swann Raises Price Target on Regeneron (REGN) to $182

October 22, 2012 2:26 PM EDT Send to a Friend
Get Alerts REGN Hot Sheet
Price: $303.08 -2.76%

Rating Summary:
    15 Buy, 11 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 23 | Down: 10 | New: 20
Trade REGN Now!
Join SI Premium – FREE
Leerink Swann reiterated an Outperform rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $182.00 (from $150.00).

MEDACorp conducted a survey of 50 U.S.ophthalmologists and based on the results analyst at Leerink Swan created a revenue model that suggests to that Eylea can continue to meet or beat street revenue estimates this year and next.

"Surveyed physicians still project a big step up in Eylea wet AMD market penetration over the next year. Treatment experienced patient penetration is expected to rise from 20.5% currently to 29% in one year and 33% in two years. Treatment naïve patient penetration is expected to rise from 17.5% currently to 26.6% in one year and 31.8% in two years,” said analyst Joseph P. Schwartz.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $158.24 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Add Your Comment